Try

CATALYST PHARMACEUTICALS, INC.

CPRXUnited States

45 filed reports · 392 financial concepts

Latest figures

Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.

FigureLatest fiscal yearLatest quarter
Revenue$589MFY2025 · to Dec 31, 2025+19.8% from $492M10-K$149MQ1 FY2026 · to Mar 31, 2026+5.6% from $141M10-Q
Net income$214MFY2025 · to Dec 31, 2025+30.8% from $164M10-K/A$63.7MQ1 FY2026 · to Mar 31, 2026+12.3% from $56.7M10-Q
Operating income$258MFY2025 · to Dec 31, 2025+32.1% from $195M10-K$73.2MQ1 FY2026 · to Mar 31, 2026+15.6% from $63.4M10-Q

Filed reports

45 reports · Jun 2015 to Mar 2026

Each report counts once it has at least one extracted financial fact.

Report typeReportsFactsPeriods
Quarterly · 10-QSEC EDGAR334,231Jun 2015 to Mar 2026
Annual · 10-KSEC EDGAR113,733Dec 2015 to Dec 2025
Annual · 10-K/ASEC EDGAR127Dec 2025

Documents

PeriodTypePeriod endPublishedFactsSource
FY2026 Q110-QMar 31, 2026May 11, 2026374Open
FY202510-K/ADec 31, 2025Apr 30, 202627Open
FY202510-KDec 31, 2025Feb 25, 2026720Open
FY2025 Q310-QSep 30, 2025Nov 5, 2025243Open
FY2025 Q210-QJun 30, 2025Aug 6, 2025209Open
FY2025 Q110-QMar 31, 2025May 7, 2025155Open
FY202410-KDec 31, 2024Feb 26, 2025371Open
FY2024 Q310-QSep 30, 2024Nov 6, 2024166Open
FY2024 Q210-QJun 30, 2024Aug 7, 2024143Open
FY2024 Q110-QMar 31, 2024May 8, 2024162Open
FY202310-KDec 31, 2023Feb 28, 2024364Open
FY2023 Q310-QSep 30, 2023Nov 8, 2023172Open

Financial data

392 concepts · 7,991 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

Financial390 concepts · 7,866 facts · Dec 2013 to Mar 2026

  • Net income loss64 · Dec 2013 to Mar 2026
  • Operating income loss64 · Dec 2013 to Mar 2026
  • Depreciation63 · Dec 2013 to Mar 2026
  • Income tax expense benefit63 · Dec 2013 to Mar 2026
  • Other nonoperating income expense63 · Dec 2013 to Mar 2026
  • Research and development expense63 · Dec 2013 to Mar 2026
  • Share based compensation63 · Dec 2013 to Mar 2026
  • Cash and cash equivalents at carrying value62 · Dec 2013 to Mar 2026
  • Antidilutive securities excluded from computation of earnings per share amount61 · Dec 2013 to Mar 2026
  • Income loss from continuing operations before income taxes extraordinary items noncontrolling interest61 · Dec 2013 to Mar 2026
  • Increase decrease in accounts payable61 · Dec 2013 to Mar 2026
  • Increase decrease in accrued liabilities and other operating liabilities61 · Dec 2013 to Mar 2026
  • Increase decrease in prepaid deferred expense and other assets61 · Dec 2013 to Mar 2026
  • Revenue60 · Dec 2013 to Mar 2026
  • Stockholders equity (US GAAP)59 · Dec 2013 to Mar 2026
  • Accounts payable current57 · Dec 2014 to Mar 2026
  • Accrued Non Clinical And Clinical Trial Expenses57 · Dec 2014 to Mar 2026
  • Accrued professional fees current57 · Dec 2014 to Mar 2026
  • Additional paid in capital57 · Dec 2014 to Mar 2026
  • Assets57 · Dec 2014 to Mar 2026
  • Assets current57 · Dec 2014 to Mar 2026
  • Common stock par or stated value per share57 · Dec 2014 to Mar 2026
  • Common stock shares authorized57 · Dec 2014 to Mar 2026
  • Common stock shares issued57 · Dec 2014 to Mar 2026

Product1 concept · 122 facts · Dec 2018 to Mar 2026

  • Revenue122 · Dec 2018 to Mar 2026

Geography1 concept · 3 facts · Dec 2018 to Dec 2020

  • Revenue From Collaborative Product3 · Dec 2018 to Dec 2020

Segments

125 facts

Figures broken down by business line, region, product or another axis the company reports on.

Product or service8 members · 122 facts

  • product revenue,net32 · Dec 2019 to Mar 2026
  • License and other revenue [Member]28 · Dec 2019 to Mar 2026
  • FIRDAPSE [Member]22 · Dec 2021 to Mar 2026
  • FYCOMPA [Member]22 · Dec 2021 to Mar 2026
  • AGAMREE [Member]11 · Mar 2024 to Mar 2026
  • License and other [Member]4 · Sep 2020 to Sep 2021
  • Collaborative Arrangement Product Agreement [Member]2 · Dec 2018 to Dec 2019
  • Product [Member]1 · Dec 2019

Statement geographical1 member · 3 facts

  • Canada [Member]3 · Dec 2018 to Dec 2020

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

No commentary or risk-factor text for this company.

Earnings calls

Transcripts with management claims and analyst questions, one per fiscal period.

No earnings-call transcripts for this company.

Executive media

Podcasts, interviews and conference appearances by the company's executives, with their claims.

No media appearances for this company.

Ask about this company in your AI model

Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.

Use FactIQ to get the revenue, net income and operating income of CATALYST PHARMACEUTICALS, INC. (CPRX) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 16, 2026) and refreshed every few hours.